Gritstone Oncology, Inc. License Agreements
5 Contracts & Agreements
- Amendment No.1 to Nonexclusive License and Development Agreement between the Company and Genevant Sciences GmbH, dated as of January 29, 2021 (Filed With SEC on November 8, 2023)
- Nonexclusive License and Development Agreement between the Company and Genevant Sciences GmbH, dated as of January 15, 2021 (Filed With SEC on November 8, 2023)
- Fourth Amendment to the License Agreement between Gritstone bio, Inc. and MIL 21E, LLC, effective as of June 30, 2022 (Filed With SEC on August 4, 2022)
- Amendment Number One to License Agreement, dated as of July 20, 2018, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva... (Filed With SEC on August 23, 2018)
- License Agreement, dated as of October 16, 2017, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva Biotherapeutics Inc (Filed With SEC on August 23, 2018)
